M&A Deal Summary |
|
|---|---|
| Date | 2024-11-07 |
| Target | Officinae Bio - DNA and RNA business |
| Sector | Life Science |
| Buyer(s) | Maravai |
| Sellers(s) | Officinae Bio |
| Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2020 |
| Sector | Life Science |
| Employees | 570 |
| Revenue | 259M USD (2024) |
Maravai is a life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to many biopharmaceutical, vaccines, diagnostics, and cell and gene therapy companies. Maravai was founded in 2020 and is based in San Diego, California.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 5 |
| Sector (Life Science) | 4 of 4 |
| Type (Divestiture) | 1 of 1 |
| Country (Italy) | 1 of 1 |
| Year (2024) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-01-28 |
MyChem
San Diego, California, United States MyChem is a privately held provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics, and research markets. MyChem products include modified nucleotides and other inputs used for mRNA synthesis. MyChem is based in San Diego, California. |
Buy | $240M |
Officinae Bio is a privately held technology company with a proprietary digital platform to support the biological design of therapeutics. Officinae Bio enables rapid prototyping of mRNA candidates to test diverse combinations of CAP analogs, chemistry modifications, and sequence designs for client discovery programs. Officinae Bio was founded in 2020 and is based in Venice, Italy.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (Italy) | 1 of 1 |
| Year (2024) | 1 of 1 |
